Zynex (NASDAQ:ZYXI) Releases Q4 Earnings Guidance

Zynex (NASDAQ:ZYXI) issued an update on its fourth quarter earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of at least $0.09 for the period, compared to the consensus estimate of $0.10. The company issued revenue guidance of at least $53.6 million, compared to the consensus revenue estimate of $53.30 million. Zynex also updated its FY 2024 guidance to 0.200- EPS.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Royal Bank of Canada cut their price objective on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. HC Wainwright lifted their price target on Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a report on Friday.

Zynex Stock Up 6.2 %

Shares of ZYXI stock traded up $0.53 during mid-day trading on Friday, hitting $9.12. 264,477 shares of the stock traded hands, compared to its average volume of 173,892. The stock’s fifty day moving average is $8.01 and its two-hundred day moving average is $9.20. The company has a debt-to-equity ratio of 1.79, a current ratio of 4.06 and a quick ratio of 3.22. Zynex has a 52-week low of $7.04 and a 52-week high of $13.77. The stock has a market cap of $289.79 million, a P/E ratio of 39.65 and a beta of 0.54.

Zynex (NASDAQ:ZYXI) last announced its earnings results on Thursday, October 24th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.01. Zynex had a net margin of 3.12% and a return on equity of 14.15%. The company had revenue of $49.97 million during the quarter, compared to the consensus estimate of $50.83 million. During the same period last year, the firm earned $0.10 earnings per share. Zynex’s revenue was up .1% compared to the same quarter last year. Equities analysts predict that Zynex will post 0.2 EPS for the current year.

Insider Buying and Selling

In other Zynex news, COO Anna Lucsok sold 8,083 shares of the stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $8.03, for a total value of $64,906.49. Following the completion of the sale, the chief operating officer now directly owns 16,980 shares in the company, valued at approximately $136,349.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Zynex news, COO Anna Lucsok sold 8,083 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $8.03, for a total transaction of $64,906.49. Following the transaction, the chief operating officer now owns 16,980 shares in the company, valued at approximately $136,349.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Joshua R. Disbrow acquired 7,000 shares of the stock in a transaction dated Monday, July 29th. The shares were bought at an average price of $8.32 per share, with a total value of $58,240.00. Following the completion of the purchase, the director now directly owns 72,000 shares of the company’s stock, valued at approximately $599,040. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 52.13% of the stock is owned by company insiders.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.